Biomea Fusion Inc., a clinical-stage diabetes and obesity medicines company, announced new preclinical findings from a 28-day weight loss study involving its investigational oral GLP-1 receptor agonist candidate, BMF-650. The study, conducted in obese cynomolgus monkeys, demonstrated significant dose-dependent reductions in food intake and marked weight loss, with average reductions of 12% and 15% over the treatment period. The data suggest that BMF-650 compares favorably to other leading GLP-1 receptor agonist candidates in development. Biomea Fusion plans to submit an Investigational New Drug $(IND.AU)$ application in the second half of 2025, with a Phase I trial in obese, otherwise healthy volunteers expected to begin in late 2025, pending IND clearance. The full set of preclinical data is scheduled for submission and presentation at an upcoming medical conference.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。